Ambroxol chaperones GCase; in a previous study of people with Parkinson's disease, the drug led to increased GCase levels. It ...

A 12-month study found that Ambroxol helped stabilised psychiatric symptoms and protected against brain damage in genetically ...

A clinical trial has revealed that Ambroxol, a common cough medicine in Europe, may help slow cognitive decline in people with Parkinson’s disease dementia.

Researchers at Lawson Research Institute (Lawson), the research arm of St. Joseph's Health Care London, are investigating ...

Dementia poses a major health challenge with no safe, affordable treatments to slow its progression. Researchers at Lawson ...

A cough medicine used for decades in Europe called Ambroxol has shown promise for treating dementia in people with ...

A COMMON cough medicine could help protect against dementia. A study found that it prevented people with Parkinson’s develop ...

Ambroxol, a common cough medicine used in Europe, demonstrated target engagement in people with Parkinson's disease dementia but did not show an effect on cognition compared with placebo, a year ...

A commonly sold cough syrup in Europe could potentially slow down progression of dementia in patients with Parkinson’s ...

Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson's disease, GCase levels are often low.

Ambroxol supports a key enzyme called glucocerebrosidase (GCase), which is produced by the GBA1 gene. In people with Parkinson's disease, GCase levels are often low.